The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effects of weekly bevacizumab and gemcitabine/oxaliplatin with or without dasatinib on heavily pretreated patients with recurrent or persistent cervical cancer.
Masashi Takano
No relevant relationships to disclose
Yoshihiro Kikuchi
No relevant relationships to disclose
Yuji Ikeda
No relevant relationships to disclose
Naoki Sasaki
No relevant relationships to disclose
Tomoko Goto
No relevant relationships to disclose
Hiroko Kouta
No relevant relationships to disclose
Ryoko Kikuchi
No relevant relationships to disclose
Kazuya Kudoh
No relevant relationships to disclose
Tsunekazu Kita
No relevant relationships to disclose
Kenichi Furuya
No relevant relationships to disclose